Side Effects & Safety Mild GI discomfort most common, usually transient in the first week Slight stimulant effect increased energy/alertness, especially early on Headaches occasional, typically mild and dose-related Mild insomnia if taken too late in the day No human clinical safety data all safety information from preclinical studies and community reports No liver toxicity observed in animal studies at therapeutic doses Unknown drug interactions theoretically could interact with NAD+-dependent pathways Core Supplies for This Protocol The essentials for running any reconstituted injectable: cold storage, accurate syringes, alcohol prep pads, and metabolic tracking
In states of obesity and metabolic dysfunction, NNMT is often overexpressed in adipose tissue, depleting nicotinamide and reducing NAD+ availability
AOD9604 PEPTIDE LIQUID SPRAY 15ML BOTTLE 0 out of 5 $62.99 $84.99Price range: $62.99 through $84.99 AOD9604 is sold for laboratory research use only
Stress and long work hours made recovery challenging
However, on July 23-24, 2026, the FDAs Pharmacy Compounding Advisory Committee (PCAC) voted on inclusion of two of GLOWs peptide compounds for the 503A Bulks List: BPC-157 : 8-6 voted in favor of inclusion, with one abstention TB-500 : 8-6 voted in favor of inclusion, with one abstention Note: TB-500 is a fragment of the full-length thymosin beta-4 (43 amino acids)